Helix BioPharma Corp. Initiates OTCQB Application and Hires U.S. Investor Relations Firm
May 30 2019 - 5:48PM
Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an
immuno-oncology company developing innovative drug candidates for
the prevention and treatment of cancer, announced that it has
commenced the process to have the Company’s common shares quoted on
the OTCQB® Market exchange in the United States. The Company’s U.S.
legal counsel, Sheppard Mullin, Richter and Hampton LLC will be
acting as Principal American Liaison (“PAL”) in assisting the
Company through the listing application process. Pending due
diligence and fulfilling various regulatory requirements,
management believes the process should take no more than two
months.
Expanding to the OTCQB® will provide existing
shareholders with an additional trading platform to the Toronto
Stock Exchange in addition to introducing the Company to a broader
range of institutional and retail investors in the U.S. Listing on
the OTCQB® represents a first step in fulfilling the Company’s
ambitions to list on a U.S. stock exchange, such as NASDAQ.
The Company is also pleased to announce that it
has retained the services of Alpha Bronze LLC to act as investor
relations agent. Alpha Bronze LLC and the Company are planning a
series of investment community outreach in the coming months. These
activities will include non-deal road shows and conference
presentations. This is part of the Company’s effort to raise
capital to further advance the Company’s clinical development
programs.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology
company specializing in the field of cancer therapy. The Company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix’s
product development initiatives include its novel L-DOS47 new drug
candidate and Chimeric Antigen Receptor (“CAR”) based cell
therapies. Helix is currently listed on the TSX under the symbol
“HBP”.
Investor Relations
Helix BioPharma Corp.9120 Leslie Street, Suite
205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300Email:
ir@helixbiopharma.com
Cautionary Statements
This news release may contain forward-looking
statements with respect to Helix, its operations, strategy,
financial performance and condition, including its activities
relating to its drug development program, any anticipated timelines
for the commencement or completion of certain activities such as
raising sufficient capital, merger and acquisition activity,
listing on a U.S. exchange and other information in future periods.
These statements generally can be identified by use of
forward-looking words such as “ambitions”, “should”, “may”, “will”,
“expect”, “estimate”, “anticipate”, “intends”, “believe” or
“continue” or the negative thereof or similar variations. The
actual results and performance of discussed herein could differ
materially from those expressed or implied by such statements. Such
statements are qualified in their entirety by the inherent risks
and uncertainties surrounding future expectations, including: (i)
Helix’s ability to operate as a going concern being dependent
mainly on securing sufficient additional financing in order to fund
its ongoing research and development and other operating
activities; (ii) the generally inherent uncertainty involved in
scientific research and drug development and those specific to
Helix’s pre-clinical and clinical development programs (DOS47,
L-DOS47, V-DOS47 and CAR-T); (iii) that any transactions
contemplated herein are completed; and (iv) those risks and
uncertainties affecting Helix as more fully described in Helix’s
most recent Annual Information Form, which is available at
www.sedar.com (together, the “Helix Risk Factors”). Certain
material factors and assumptions are applied in making the
forward-looking statements, including, without limitation, that
sufficient financing will be obtained in a timely manner to allow
Helix to continue operations and implement its clinical trials in
the manner and on the timelines anticipated and that the Helix Risk
Factors will not cause Helix’s actual results or events to differ
materially from the forward-looking statements. These cautionary
statements qualify all such forward-looking statements.
Forward-looking statements and information are
based on the beliefs, assumptions, opinions, plans and expectations
of Helix’s management on the date of this news release, and the
Company does not assume any obligation to update any
forward-looking statement or information should those beliefs,
assumptions, opinions, plans or expectations, or other
circumstances change, except as required by law.
Huttig Building Products (NASDAQ:HBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Huttig Building Products (NASDAQ:HBP)
Historical Stock Chart
From Jul 2023 to Jul 2024